Lycia Therapeutics, Inc. (LYCA) Stock Price & Analysis
Lycia Therapeutics, Inc. (LYCA) closed at USD 26.4 on Friday, October 30, 2026, down 4.80% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 27.73; the Oct 30, 2026 session ranged USD 25.66–27.59 on volume of 202,427 shares. Market capitalization is $1.38B, with a 52-week range of USD 22.19–36.49 (NMS). Source: Nexqual, retrieved October 31, 2026 at 00:27 UTC.
Also available as compact Markdown for AI agents: nexqual.com/LYCA.md
Key facts (LYCA)
- Insider open-market purchases, last ~7 months: 2 Form 4 filings, $38.3M; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: None.
- Total return with dividends: 1Y -7.6% vs S&P 500 +14.0%; 5Y -12.0% vs S&P 500 +72.5%.
- Dividend: LYCA paid no cash dividend in the last five years.
Insider purchases (SEC Form 4, open-market, last ~7 months) (LYCA)
2 purchases, $38.3M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-10-28…2026-10-30 | Venrock Healthcare Capital Partners Iii, L.P. | 25,004 | $645K | 25.78 | Too little history (no open-market trades in 2023–2025) | |
| 2026-10-23…2026-10-27 | Venrock Healthcare Capital Partners Iii, L.P. | 2,045,440 | $37.7M | 18.41 | Too little history (no open-market trades in 2023–2025) |
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (LYCA)
Consensus None.
Total return (dividends reinvested) (LYCA)
| 1Y (from 2026-10-23) | 5Y (from 2026-10-19) | |
|---|---|---|
| Total return | -7.6% | -12.0% |
| S&P 500 (SPY) | +14.0% | +72.5% |
| Per year | — | — |
| Volatility (annualized) | 135.9% | 15.1% |
| Max drawdown | -16.5% (Oct 2026→Oct 2026) | -12.0% (Oct 2026→Oct 2026) |
Dividends (LYCA)
LYCA paid no cash dividend in the last five years.
LYCA recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 30, 2026 | Schedule 13G | Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC: 11.9% of shares, passive 5%+ holder |
| Oct 26, 2026 | 8-K | Bylaws or fiscal-year change |
| Oct 20, 2026 | S-1/A | Registration of new shares |
| Oct 5, 2026 | S-1 | Registration of new shares |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
LYCA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 31, 2026 at 00:27 UTC)
| Price | USD 26.4 |
|---|---|
| Change | ▼ 4.80% (down) |
| Previous Close | USD 27.73 |
| Open | USD 26.28 |
| Day Range | USD 25.66 – 27.59 |
| 52-Week Range | USD 22.19 – 36.49 |
| Volume | 202,427 shares |
| Market Cap | $1.38B |
| Exchange | NMS |
Analyst Ratings (LYCA)
Wall Street analysts rate LYCA "None", per Nexqual as of October 31, 2026 at 00:27 UTC.
| Consensus Rating | None |
|---|
Earnings (LYCA)
Source: Nexqual, October 31, 2026 at 00:27 UTC.
Financials & Fundamentals (LYCA)
| Total Revenue | $4.43M |
|---|---|
| Gross Margin | +291.48% |
| Operating Margin | -762.32% |
| Profit Margin | +0.00% |
| Debt / Equity | 0.02 |
| Current Ratio | 12.6 |
| Total Cash | $124.32M |
| Total Debt | $3.16M |
Source: Nexqual, October 31, 2026 at 00:27 UTC.
Financial Health Score (LYCA)
Nexqual rates Lycia Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 31, 2026 at 00:27 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $124M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$34M (TTM) |
| Efficiency | Mixed — No data |
Ownership (LYCA)
| Insider Ownership | +7.77% |
|---|---|
| Institutional Ownership | +39.24% |
| Shares Outstanding | 52.09M |
| Float | 8.85M |
Source: Nexqual, October 31, 2026 at 00:27 UTC.
Leadership (LYCA)
Lycia Therapeutics, Inc. is led by Aetna Wun Trombley, CEO, Secretary, President & Director, per Nexqual as of October 31, 2026 at 00:27 UTC.
| CEO, Secretary, President & Director | Aetna Wun Trombley |
|---|---|
| Chief Financial Officer | Amy Bachrodt |
| Senior Vice President of Finance | Winsome Chung |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 92.57 | ▼ 0.54% |
| ORKA | Oruka Therapeutics, Inc. | USD 96.87 | ▲ 0.23% |
| LGND | Ligand Pharmaceuticals Incorpor | USD 322.75 | ▲ 1.71% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.52 | ▼ 1.96% |
| AXSM | Axsome Therapeutics, Inc. | USD 144.43 | ▲ 0.68% |
| ABVX | Abivax SA | USD 86.59 | ▼ 2.77% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 31, 2026 at 00:27 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt